ArticleInternational journal of molecular and cellular medicine2020
Circulating CYTOR as a Potential Biomarker in Breast Cancer.
Article in International journal of molecular and cellular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Pooled it
- The clinical significance of circulating DSCAM-AS1 in patients with ER-positive breast cancer and construction of its competitive endogenous RNA network.Molecular biology reports · 2020Trial
- Role of exercise on the reduction of cancer development: a mechanistic review from the lncRNA point of view.Clinical and experimental medicine · 2025Review
- Long non-coding RNAs: Key regulators of stemness in breast cancer.Frontiers in cell and developmental biology · 2025Review
- Restoring Tamoxifen Sensitivity in Breast Cancer: The Role of lncRNA MALAT1 and NanoCurcumin as Modulators of Drug Resistance.BioMed research international · 2025Article
- lncRNAs as prognostic markers and therapeutic targets in cuproptosis-mediated cancer.Clinical and experimental medicine · 2024Review
- Integrative Analysis Revealed LINC00847 as a Potential Target of Tumor Immunotherapy.Applied biochemistry and biotechnology · 2023Article
- Article
- Expression Level of lncRNA CYTOR in Iranian Cervical Cancer Patients.Reports of biochemistry & molecular biology · 2023Article
- Application value of circulating LncRNA in diagnosis, treatment, and prognosis of breast cancer.Functional & integrative genomics · 2023Review
- Comprehensive analysis of NJournal of clinical laboratory analysis · 2021Article
- lncRNA cytoskeleton regulator reduces non‑small cell lung cancer radiosensitivity by downregulating miRNA‑206 and activating prothymosin α.International journal of oncology · 2021Article
- Article
- Using immune-related lncRNAs to construct novel biomarkers and investigate the immune landscape of breast cancer.Translational cancer research · 2021Article
- Non-Coding RNA Signatures of B-Cell Acute Lymphoblastic Leukemia.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long non-coding RNAs (lncRNAs) are newly introduced as tumor-related molecules. They are being considered as potential diagnostic and therapeutic targets in cancer studies. Here, we have assessed the importance of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.